Lung Cancer

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Xiuning Le, MD, PhD, discusses the mechanism of action of sevabertinib in HER2-mutated NSCLC.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

The FDA has accepted a BLA seeking the approval of ivonescimab plus chemotherapy for EGFR-mutated, advanced, nonsquamous NSCLC after TKI progression.

Enriqueta Felip, MD, PhD, discusses key efficacy data from the MARIPOSA trial and its implications.

Enriqueta Felip, MD, PhD, discusses EGFR-mutated non-small cell lung cancer and how to approach it from multiple angles.

Gotistobart received orphan drug designation from the FDA for patients with squamous NSCLC.

Xiuning Le, MD, PhD, discusses the significance of the FDA’s approval of sevabertinib for locally advanced/metastatic, nonsquamous HER2-positive NSCLC.

Eric K. Singhi, MD, discuses the emerging role of TROP2-directed antibody–drug conjugates in the evolving treatment algorithm for NSCLC.

Laura Alder, MD, discusses clinical decision-making around prioritizing local vs systemic therapy for patients with lung cancer who present with CNS-only metastatic disease.

Lung cancer experts stress the importance of lung cancer screening and discuss ways that technological advances are transforming screening processes and outcomes.

Experts discuss the latest advancements in early lung cancer screening, including biomarkers and technologies that enhance detection and patient outcomes.

Xiuning Le, MD, PhD, discusses the FDA approval of sevabertinib for pretreated, advanced, nonsquamous NSCLC with tumors harboring HER2 TKD mutations.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

Nogapendekin alfa inbakicept plus an immune checkpoint inhibitor generated absolute lymphocyte count increases in non–small cell lung cancer.

An international group of thoracic oncology specialists reviewed key updates in first-line NSCLC from the 2025 ESMO Asia Congress.

A BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC following treatment with a third-generation EGFR TKI has been submitted to the FDA.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Explore the complex case of a 70-year-old woman battling metastatic adenocarcinoma, highlighting treatment challenges and HER2 testing results.

Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D–mutated locally advanced or metastatic NSCLC.

Joshua K. Sabari, MD, discusses the significance of the FDA approval of subcutaneous amivantamab for the treatment of patients with EGFR-mutant NSCLC.

Sac-TMT plus pembrolizumab has earned breakthrough therapy designation in China in frontline EGFR- and ALK-negative PD-L1+ NSCLC.